Anti-hepatitis C virus drugs in development

Gastroenterology

Volumn 142, Issue 6, 2012, Pages

  Schaefer, Esperance A K ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Host Targeted Anti Virals; NS5A Inhibitors; NS5B Inhibitors; Protease Inhibitors

Indexed keywords

ABT 072; ABT 333; ABT 450; ACH 1625; ANTIVIRUS AGENT; ASUNAPREVIR; BI 201335; BI 207127; BOCEPREVIR; CYCLOPHILIN INHIBITOR; DACLATASVIR; DANOPREVIR; FILIBUVIR; GS 9256; GS 9451; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDX 184; MERICITABINE; MK 5172; NARLAPREVIR; PEGINTERFERON ALPHA; PLACEBO; PSI 7977; RIBAVIRIN; RITONAVIR; SETROBUVIR; SIMEPREVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VX 222;

ANEMIA; ANTIVIRAL RESISTANCE; BILIRUBIN BLOOD LEVEL; DIARRHEA; DRUG BINDING SITE; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DYSGEUSIA; ENZYME ACTIVITY; FATIGUE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAUNDICE; LIFE CYCLE; MIXED INFECTION; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; PHOSPHORYLATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RELAPSE; REVIEW; RNA SYNTHESIS; RNA VIRUS; SIDE EFFECT; TREATMENT DURATION; VIRUS GENE; VIRUS MORPHOLOGY; VIRUS REPLICATION; VOMITING;

EID: 84860307792     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.02.015     Document Type: Article

References (116)

1. A. Hatzakis, S. Wait, J. Bruix The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * J Viral Hepat 18 Suppl 1 2011 1 16
2. K. Page, J.A. Hahn, J. Evans Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection J Infect Dis 200 2009 1216 1226
3. C.C. Wang, E. Krantz, J. Klarquist Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance J Infect Dis 196 2007 1474 1482
4. T. Kagawa, E.B. Keeffe Long-term effects of antiviral therapy in patients with chronic hepatitis C Hepat Res Treat 2010 2010 562 578
5. N. Hayashi, T. Takehara Antiviral therapy for chronic hepatitis C: past, present, and future J Gastroenterol 41 2006 17 27
6. T. Wakita, T. Pietschmann, T. Kato Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Nat Med 11 2005 791 796
7. B.D. Lindenbach, P. Meuleman, A. Ploss Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro Proc Natl Acad Sci U S A 103 2006 3805 3809
8. A. Merz, G. Long, M.S. Hiet Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome J Biol Chem 286 2011 3018 3032
9. A.W. Tai, Y. Benita, L.F. Peng A functional genomic screen identifies cellular cofactors of hepatitis C virus replication Cell Host Microbe 5 2009 298 307
10. J. Ye, C. Wang, R. Sumpter Jr Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc Natl Acad Sci U S A 100 2003 15865 15870
11. E. Herker, M. Ott Unique ties between hepatitis C virus replication and intracellular lipids Trends Endocrinol Metab 22 2011 241 248
12. R.E. Lanford, E.S. Hildebrandt-Eriksen, A. Petri Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Science 327 2010 198 201
13. J.M. Pawlotsky Hepatitis C virus genetic variability: pathogenic and clinical implications Clin Liver Dis 7 2003 45 66
14. L. Rong, H. Dahari, R.M. Ribeiro Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra2
15. T. Kuntzen, J. Timm, A. Berical Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
16. J.G. McHutchison, G.T. Everson, S.C. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
17. J.G. McHutchison, M.P. Manns, A.J. Muir Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
18. I.M. Jacobson, J.G. McHutchison, G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
19. F. Poordad, J. McCone Jr, B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
20. B.R. Bacon, S.C. Gordon, E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
21. V. Garg, R. van Heeswijk, J.E. Lee Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus Hepatology 54 2011 20 27
22. D.L. Thomas, J.G. Bartlett, M.G. Peters Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons Clin Infect Dis 2012 Feb 4 [Epub ahead of print]
23. C. Sarrazin, T.L. Kieffer, D. Bartels Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777
24. S. Susser, C. Welsch, Y. Wang Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
25. H.W. Reesink, S. Zeuzem, C.J. Weegink Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study Gastroenterology 131 2006 997 1002
26. G.R. Foster, C. Hezode, J.P. Bronowicki Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 2011 881 889 e1
27. J.M. Gottwein, T.K. Scheel, T.B. Jensen Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses Gastroenterology 141 2011 1067 1079
28. Y. Benhamou, J. Moussali, V. Raziu Activity of telaprevir or in combination with peginterferon-alfa-2a and ribavirin the treatment-nave genotype 4 hepatitis-C patients: final results of Study C210 Presented as the American Association for the Study of Liver Diseases, Boston, MA November 2010
29. S. Ciesek, T. von Hahn, M.P. Manns Second-wave protease inhibitors: choosing an heir Clin Liver Dis 15 2011 597 609
30. P. Halfon, S. Locarnini Hepatitis C virus resistance to protease inhibitors J Hepatol 55 2011 192 206
31. T.I. Lin, O. Lenz, G. Fanning In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrobial agents and chemotherapy 53 2009 1377 1385
32. M.W. Fried, M. Buti, G.J. Dore Efficacy and safety of TMC435 in combination with PEG-interferon alpha-2A and ribavirin in treatment naive genotype 1 HCV patients: 24 week interim results from the PILLAR trial Presented as the American Association for the Study of Liver Diseases, Boston, MA November 2010
33. M.W. Fried, M. Buti, G.J. Dore TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIb study Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 7, 2011
34. Y.S. Tsantrizos TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection Curr Opin Invest Drugs 10 2009 871 881
35. Medivir Announces Positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-Naive Patients Chronically Infected With Genotype-1 Hepatitis C Virus 2011 http://www.natap.org/2011/HCV/022211-02.htm Accessed October 2011
36. N. Forestier, D. Larrey, P. Marcellin Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C J Infect Dis 204 2011 601 608
37. E.J. Gane, R. Rouzier, C. Stedman Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients J Hepatol 55 2011 972 979
38. E.J. Gane, S.K. Roberts, C.A. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
39. S. Zeuzem, T. Asselah, P. Angus Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 141 2011 2047 2055 quiz e14
40. C. Sarrazin, S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
41. O. Lenz, T. Verbinnen, T.I. Lin In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob Agents Chemother 54 2010 1878 1887
42. G. Kukolj, G.A. McGibbon, G. McKercher Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase J Biol Chem 280 2005 39260 39267
43. S. Ali, V. Leveque, S. Le Pogam Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479 Antimicrob Agents Chemother 52 2008 4356 4369
44. K. Klumpp, G. Kalayanov, H. Ma 2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups J Biol Chem 283 2008 2167 2175
45. A.M. Lam, C. Espiritu, S. Bansal HCV nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA J Virol 85 2011 12334 12342
46. S. Le Pogam, A. Seshaadri, A. Ewing RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients J Infect Dis 202 2010 1510 1519
47. D.M. Jensen, H. Wedemeyer, R.W. Herring High rates of early viral reponse, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PEGIFN Alfa-2a/RBV: planned week 12 interim analysis from the PROPEL Study Presented as the American Association for the Study of Liver Diseases, Boston, MA November 2010
48. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PegIFN/RBV in a phase 2B trial: rapid virologic suppression in treatment-nave patients with HCV GT2/GT3. Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011.
49. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PegIFN/RBV in a Phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3.
50. E. Gane, C.A. Stedman, R.H. Hyland Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or 3 Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 6, 2011
51. J.A. Ilyas, J.M. Vierling An overview of emerging therapies for the treatment of chronic hepatitis C Clin Liver Dis 15 2011 515 536
52. B.H. McGovern, B.K. Abu Dayyeh, R.T. Chung Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection Hepatology 48 2008 1700 1712
53. F.E. Membreno, E.J. Lawitz The HCV NS5B nucleoside and non-nucleoside inhibitors Clin Liver Dis 15 2011 611 626
54. I.M. Jacobson Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2a and ribavirin in chronically infected HCV genotype 1 patients Presented at the European Association for the Study of the Liver, International Liver Conference, Vienna, Austria, April 2010
55. E. Lawitz A Phase 2b trial comparing 24 to 48 weeks of treatment with tegobuvir (GS-9190)/PEG/RV to 48 weeks treatment with PEG/RBV for chronic genotype 1 HCV infection Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011
56. R.A. Fridell, D. Qiu, L. Valera Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 J Virol 85 2011 7312 7320
57. P. Ferraris, E. Blanchard, P. Roingeard Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes J Gen Virol 91 2010 2230 2237
58. A. Macdonald, M. Harris Hepatitis C virus NS5A: tales of a promiscuous protein J Gen Virol 85 2004 2485 2502
59. K.H. Lan, K.L. Lan, W.P. Lee HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines J Hepatol 46 2007 759 767
60. R.G. Gish, N.A. Meanwell The NS5A replication complex inhibitors: difference makers? Clin Liver Dis 15 2011 627 639
61. M. Gao, R.E. Nettles, M. Belema Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
62. Pol S, Ghalib RH, Rustgi VK, et al. First report of SVR12 for a NS5A replication complex inhibitor, BMS-790052 in combination with peg-IFN-alfa-2a and RBV: phase 2a trial in treatment-naive HCV-genotype 1 subjects. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011). Berlin. March 30-April 3.
63. R.E. Nettles, M. Gao, M. Bifano Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 54 2011 1956 1965
64. R.A. Fridell, C. Wang, J.H. Sun Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 54 2011 1924 1935
65. J. Chayama, S. Takahashi, Y. Kawakami Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% SVR12 in HCV genotype 1b-infected null reponders Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 7, 2011
66. D. Ge, J. Fellay, A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
67. V. Suppiah, M. Moldovan, G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
68. A. Rauch, Z. Kutalik, P. Descombes Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345 45 e1-e7
69. Y. Tanaka, N. Nishida, M. Sugiyama Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
70. D.L. Thomas, C.L. Thio, M.P. Martin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
71. H.L. Tillmann, A.J. Thompson, K. Patel A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice Gastroenterology 139 2010 1586 1592 92 e1
72. S.V. Kotenko, G. Gallagher, V.V. Baurin IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 2003 69 77
73. P. Sheppard, W. Kindsvogel, W. Xu IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 2003 63 68
74. H.H. Gad, C. Dellgren, O.J. Hamming Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family J Biol Chem 284 2009 20869 20875
75. L. Zhang, N. Jilg, R.X. Shao IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway J Hepatol 55 2011 289 298
76. S.E. Doyle, H. Schreckhise, K. Khuu-Duong Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes Hepatology 44 2006 896 906
77. T. Marcello, A. Grakoui, G. Barba-Spaeth Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 131 2006 1887 1898
78. C. Sommereyns, S. Paul, P. Staeheli, T. Michiels IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo PLoS Pathogens 4 2008 e1000017
79. A.J. Muir, M.L. Shiffman, A. Zaman Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection Hepatology 52 2010 822 832
80. M. Rodriguez-Torres, J.L. Hillson, P.R. Bacon Safety and efficacy of pegylated interferon lambda compared to pegylated interferon alfa 2a in HCV infected patients (G1/2/3) with compensated cirrhosis: EMERGE Phase IIB efficacy and safety results through week 12 Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011
81. S. Teraoka, S. Mishiro, K. Ebihara Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus Transpl Proc 20 1988 868 876
82. X. Hanoulle, A. Badillo, J.M. Wieruszeski Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B J Biol Chem 284 2009 13589 13601
83. S. Hopkins, B. Scorneaux, Z. Huang SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro Antimicrob Agents Chemother 54 2010 660 672
84. Hopkins S, Mosier S, Harris R, et al. Resistance selection following 15 days of monotherapy with SCY-635 a non-immunosuppressive cyclophilin inhibitor with potent anti-HCV activity. 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010). Vienna, Austria. April 14-18, 2010.
85. L. Coelmont, X. Hanoulle, U. Chatterji DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PloS One 5 2010 e13687
86. R. Flisiak, S.V. Feinman, M. Jablkowski The cyclophilin inhibitor Debio 025 combined with PEGIFN alpha2a significantly reduces viral load in treatment-naive hepatitis C patients Hepatology 49 2009 1460 1468
87. J.M. Pawlotsky, R. Flisiak, J. Rasenack Once daily alisporivir IFN-free regimens achieve high rates of early HCV clearance in previously untreated patients with genotype 2 or 3 Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 7, 2011
88. Flisiak R. Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 3, 2011.
89. Flisiak R, Pawlotsky J-M, Crabbé R, et al. Once daily alisporivir (DEB025) plus PegIFNalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011).
90. B. Li, J. Snoeck, Y. Tang Alisporivir - a host-targeting antiviral provides low viral breakthrough rate and high barrier to resistance in HCV genotype 1 treatment-naive patients in the Phase IIb ESSENTIAL study Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 7, 2011
91. H. Guo, N.T. Ingolia, J.S. Weissman, D.P. Bartel Mammalian microRNAs predominantly act to decrease target mRNA levels Nature 466 2010 835 840
92. D.P. Bartel MicroRNAs: target recognition and regulatory functions Cell 136 2009 215 233
93. C.L. Jopling, S. Schutz, P. Sarnow Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome Cell Host Microbe 4 2008 77 85
94. R.K. Jangra, M. Yi, S.M. Lemon Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122 J Virol 84 2010 6615 6625
95. H.L. Janssen, H. Reesink, S. Zeuzem A randomized, double-blind, placebo controlled safety and anti-viral proof of concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment naive patients with genotype 1 chronic HCV infection Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 7, 2011
96. L.F. Peng, E.A. Schaefer, N. Maloof Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl- coenzyme A synthase J Infect Dis 204 2011 609 616
97. M. Ikeda, K. Abe, M. Yamada Different anti-HCV profiles of statins and their potential for combination therapy with interferon Hepatology 44 2006 117 125
98. J.G. O'Leary, J.L. Chan, C.M. McMahon Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial Hepatology 45 2007 895 898
99. T. Bader, J. Fazili, M. Madhoun Fluvastatin inhibits hepatitis C replication in humans Am J Gastroenterol 103 2008 1383 1389
100. E.F. Georgescu, L. Streba, R. Teodorescu, G. Mateescu, M. Tataru Abagiu Potential enhancement of both early (EVR) and sustained (SVR) virological response by fluvastatin in chronic hepatitis C treated with standard pegIFN-ribavirin therapy A pilot study Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011
101. A.S. Lok, D. Gardiner, E. Lawitz Quadruple therapy with BMS-790052, BMS-650032, and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in genotype 1 null responders Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011
102. P. Sharma, A.S. Lok Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology 141 2011 1963 1967
103. M.S. Sulkowski, E. Ceasu, T. Asselah SILENC-1: sustained virologic response (SVR) and safety of BI201335 combined with PEGInterferon alfa-2a and ribavirin (P/R) in treatment naive patients with chronic genotype 1 HCV infection Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany April 2011
104. J.M. Vierling, F. Poordad, E. Lawitz Once daily narlaprevir and ritonavir in combination with peginterferon alfa-2b/ribavirin for 12 weeks plus 12 weeks PR in treatment naive patients with HCV gentoype 1 (G1): SVR results from NEXT-1, a Phase 2 Study Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 2011
105. P. Lalezari, L. Hazan, M. Kankam High rapid virologic response (RVR) with ACH-1625 daily dosing plus PEGIFN-alpha 2a/RBV in a 28 day Phase 2a trial Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 2011
106. D. Larrey, C. Carenco, D. Guyader High sustained virological response (SVR) rate after danoprevir for only 14 days associated with PEG-interferon alfa-2a and ribavirin in treatment-naive chronic HCV genotype 1 patients Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011
107. M.P. Manns, E.J. Gane, M. Rodriguez-Torres Sustained virologic response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C infection treated wtih Vaniprevir, a NS3/4A protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days Presented as the American Association for the Study of Liver Diseases, Boston, MA November 2010
108. E. Lawitz, I.A. Gaultier, F. Poordad ABT-450/Ritonavir (ABT-450/r) combined with pegylated interferon alpha-2a and ribavirin after 3-day monotherapy in genotype 1 HCV-infected treatment-nave subjects: 12-week interim efficacy and safety results Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011
109. J.P. Bronowicki, S. Pol, P.J. Thuluvath BMS-650032, an NS3 inhibitor, in combination with PEGinterferon alfa-2a and ribavirin in treatment naive subjects with genotype 1 chronic hepatitis C infection Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011
110. G.R. Foster, P. Buggisch, P. Marcellin Four-week treatment with GS-9256 and tegobuvir (GS-9190) +/- RBV +/- PEG, results in enhanced viral suppression on follow-up PEG/RBV therapy, in genotype 1a/1b HCV patients Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, March 2011
111. D. Graham, A. Acosta, Z. Guo MK-5172, a second generation HCV NS3/4A protease inhibitor is active against common resistance associated variants (RAVs) and exhibits cross-genotype activity Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 5, 2011
112. P. Pockros, D.M. Jensen, N. Tsai First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with PEG-inteferon/ribavirin in treatment naive GT 1/3 patients: interim analysis from the JUMP-C trial Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany April 2011
113. E. Lawitz, J. Lalezari, T. Hassanein PSI-7977 400mg with PEG/RBV provides 93% SVR across GT 1, 2, and 3 Presented at HepDart, Koloa, Hawaii December 6, 2011
114. ANA-598 HCV non-nuke Phase 2b study preliminary data results background to Phase IIb study, 2011 http://www.natap.org/2011/HCV/101411-01.htm Accessed January 11, 2012
115. T. Middleton, Y. He, J. Beyer Factors affecting HCV viral load response to the non-nucleoside polymerase inhibitors ABT-072 and ABT-033 Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011
116. D.R. Nelson, E. Gane, I.M. Jacobson VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive gentoype 1 HCV patients treated for 12 weeks: ZENITH study, SVR 12 interim analysis Presented as the American Association for the Study of Liver Diseases, San Francisco, CA November 7, 2011